Philippe Bierling

7.9k total citations
165 papers, 5.3k citations indexed

About

Philippe Bierling is a scholar working on Hematology, Genetics and Genetics. According to data from OpenAlex, Philippe Bierling has authored 165 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Hematology, 33 papers in Genetics and 26 papers in Genetics. Recurrent topics in Philippe Bierling's work include Blood groups and transfusion (88 papers), Platelet Disorders and Treatments (77 papers) and Erythrocyte Function and Pathophysiology (23 papers). Philippe Bierling is often cited by papers focused on Blood groups and transfusion (88 papers), Platelet Disorders and Treatments (77 papers) and Erythrocyte Function and Pathophysiology (23 papers). Philippe Bierling collaborates with scholars based in France, United States and Tunisia. Philippe Bierling's co-authors include Bertrand Godeau, Marc Michel, Mehdi Khellaf, Annette Schaeffer, Patricia Fromont, N. Duédari, Éric Oksenhendler, F. Noizat‐Pirenne, Catherine Cordonnier and Frédéric Galactéros and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Blood.

In The Last Decade

Philippe Bierling

158 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Bierling France 43 3.8k 1.2k 935 769 669 165 5.3k
Thomas Kühne Switzerland 34 4.6k 1.2× 746 0.6× 1.1k 1.1× 1.0k 1.3× 675 1.0× 131 6.4k
Paul Imbach Switzerland 29 5.0k 1.3× 812 0.7× 1.5k 1.6× 915 1.2× 708 1.1× 125 6.2k
Peter A. McSweeney United States 44 3.9k 1.0× 1.0k 0.8× 1.7k 1.8× 938 1.2× 382 0.6× 143 6.3k
Álvaro Urbano-Ispizúa Spain 44 3.3k 0.9× 1.3k 1.0× 2.3k 2.4× 679 0.9× 342 0.5× 215 6.1k
Lionel Galicier France 47 3.5k 0.9× 962 0.8× 3.8k 4.0× 1.2k 1.5× 617 0.9× 184 7.8k
Steven Z. Pavletic United States 45 4.8k 1.3× 1.1k 0.9× 2.0k 2.1× 584 0.8× 239 0.4× 267 7.0k
Jill Hows United Kingdom 41 7.2k 1.9× 2.2k 1.8× 2.7k 2.9× 368 0.5× 573 0.9× 101 9.8k
Douglas A. Triplett United States 37 3.9k 1.0× 336 0.3× 1.3k 1.4× 450 0.6× 843 1.3× 112 7.9k
Robert P. Witherspoon United States 48 5.7k 1.5× 1.2k 1.0× 2.3k 2.5× 465 0.6× 348 0.5× 104 8.0k
Ghulam Mufti United Kingdom 27 4.7k 1.3× 2.0k 1.6× 886 0.9× 418 0.5× 491 0.7× 101 5.8k

Countries citing papers authored by Philippe Bierling

Since Specialization
Citations

This map shows the geographic impact of Philippe Bierling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Bierling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Bierling more than expected).

Fields of papers citing papers by Philippe Bierling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Bierling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Bierling. The network helps show where Philippe Bierling may publish in the future.

Co-authorship network of co-authors of Philippe Bierling

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Bierling. A scholar is included among the top collaborators of Philippe Bierling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Bierling. Philippe Bierling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tamagne, Marie, et al.. (2015). Red blood cell alloimmunization is influenced by the delay between Toll-like receptor agonist injection and transfusion. Haematologica. 101(2). 209–218. 17 indexed citations
2.
Roux, S., Gwellaouen Bodivit, Nathalie Chevallier, et al.. (2014). In Vitro Characterization of Patches of Human Mesenchymal Stromal Cells. Tissue Engineering Part A. 21(3-4). 417–425. 9 indexed citations
3.
Kütük, Mehmet Serdar, Laure Croisille, Süreyya Burcu Görkem, et al.. (2014). Fetal intracranial hemorrhage related to maternal autoimmune thrombocytopenic purpura. Child s Nervous System. 30(12). 2147–2150. 8 indexed citations
4.
Bierling, Philippe, et al.. (2013). Hémovigilance donneur : quel apport pour la sécurité du donneur et du receveur. Transfusion Clinique et Biologique. 20(2). 99–103. 6 indexed citations
5.
Patel, Vivek, Matthieu Mahévas, Soo Yong Lee, et al.. (2012). Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 119(25). 5989–5995. 243 indexed citations
6.
Bodivit, Gwellaouen, et al.. (2010). Anti‐T haemolysins: the effects of sialic acid removal and 2‐aminoethylisothiouronium bromide treatment of erythrocytes on immune lysis. Vox Sanguinis. 100(4). 401–408. 8 indexed citations
7.
Bierling, Philippe, et al.. (2009). [What are the rules and regulations for blood product transfusion in France?].. PubMed. 59(1). 90–2. 3 indexed citations
8.
Traineau, R, et al.. (2009). Que reste-t-il des risques infectieux des produits sanguins?. La Revue du praticien. 59(1). 1 indexed citations
9.
Bibi, M., et al.. (2009). Platelet‐specific alloantigens and antibodies in Tunisian women after three or more pregnancies. Transfusion Medicine. 19(5). 269–273. 6 indexed citations
10.
Godeau, Bertrand, Raphaël Porcher, Olivier Fain, et al.. (2008). Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 112(4). 999–1004. 184 indexed citations
11.
Michel, Marc, et al.. (2008). Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. British Journal of Haematology. 142(4). 638–643. 54 indexed citations
12.
Bettaı̈eb, Ali, et al.. (2005). Platelet and granulocyte alloimmunisation in multitransfused Tunisian patients. European Journal Of Haematology. 75(3). 248–251. 7 indexed citations
13.
Bierling, Philippe, et al.. (1998). Transfusion de concentrés plaquettaires. 3(10). 869–877.
14.
Busson, Marc, C Hiesse, Claude Buisson, et al.. (1997). Lymphocytotoxic antibody responses to one prospective HLA-DR typed blood transfusion in naive patients awaiting renal transplantation. Transplantation Proceedings. 29(1-2). 1415–1416. 1 indexed citations
15.
Rochant, H, et al.. (1995). Purpura thrombopénique idiopathique. Hématologie. 1(4). 1 indexed citations
16.
Norol, Françoise, D. Bachir, F. Beaujean, et al.. (1994). Transfusion et alloimmunisation chez les patients drépanocytaires. Transfusion Clinique et Biologique. 1(1). 27–34. 32 indexed citations
17.
Bierling, Philippe, et al.. (1993). Influence of posttransplantation blood transfusion on kidney allograft survival: a one-center, double-blind, prospective, randomized study comparing cryopreserved and fresh red blood cell concentrates.. PubMed. 25(1 Pt 1). 616–8. 2 indexed citations
18.
Cherqui, Daniel, et al.. (1992). [Double liver-kidney transplantation in the presence of a positive T cross-match].. PubMed. 21(41). 2015–6. 3 indexed citations
19.
Durand‐Zaleski, Isabelle, et al.. (1992). Usefulness of consensus conferences: the case of albumin. The Lancet. 340(8832). 1388–1390. 35 indexed citations
20.
Oksenhendler, Éric, Philippe Bierling, Jean‐Pierre Farcet, et al.. (1987). Response to therapy in 37 patients with HIV‐related thrombocytopenic purpura. British Journal of Haematology. 66(4). 491–495. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Kühne Breakdown of academic impact, for papers by Paul Imbach Breakdown of academic impact, for papers by Peter A. McSweeney Breakdown of academic impact, for papers by Álvaro Urbano-Ispizúa Breakdown of academic impact, for papers by Lionel Galicier Breakdown of academic impact, for papers by Steven Z. Pavletic Breakdown of academic impact, for papers by Jill Hows Breakdown of academic impact, for papers by Douglas A. Triplett Breakdown of academic impact, for papers by Robert P. Witherspoon Breakdown of academic impact, for papers by Ghulam Mufti
Rankless by CCL
2026